Hydrocortisone for BPD Extubation Form in A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival Without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 22-26 Months of Age in Intubated Infants <30 Weeks Gestation Age

Hydrocortisone for BPD Extubation Form, CSV. Captures pre- and post-extubation data.
Study Description
The Hydrocortisone and Extubation study tested the safety and efficacy of a 10-day course of hydrocortisone for infants who were less than 30 weeks estimated gestational age and who were intubated at 14-28 days of life. Infants were randomized to receive hydrocortisone or placebo. The study determined that hydrocortisone treatment starting on postnatal day 14 to 28 did not result in substantially higher survival without moderate or severe bronchopulmonary dysplasia than placebo. Survival without moderate or severe neurodevelopmental impairment did not differ substantially between the two groups. Infants inborn at a network clinical center who were between 14-28 postnatal days who were <30 weeks estimated gestational age and had received ≥ 7 days of mechanical ventilation and were receiving mechanical ventilation through an endotrachel tube.